Skip to content

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$590M-0.4%
Amgen logo
AmgenAMGN
2.8B0.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$5K+25.0%
Immunome logo
ImmunomeIMNM
$11K+22.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
400M0.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$9K0.0%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's common stock?
Bicara Therapeutics (BCAX) reported common stock of 500M in Q1 2026.
How has Bicara Therapeutics's common stock changed year-over-year?
Bicara Therapeutics's common stock decreased by 0.0% year-over-year, from 500M to 500M.
What is the long-term trend for Bicara Therapeutics's common stock?
Over 2 years (2023 to 2025), Bicara Therapeutics's common stock has grown at a 49900.0% compound annual growth rate (CAGR), from 2K to 500M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).